Physician profile
Ruth Warren
NPI 1811743990
$856.16
in general payments reported to CMS, 2019-2025
14 companies · $840 in 2025
The $840 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $16.33 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $144.99 | 2025 | Ocrevus, Ocrevus Zunovo |
| Neurocrine Biosciences, INC. | $118.17 | 2025 | |
| Tg Therapeutics, INC. | $106.83 | 2025 | |
| Eisai INC. | $105.63 | 2025 | |
| Route 92 Medical, INC. | $93.48 | 2025 | |
| Vanda Pharmaceuticals INC. | $57.28 | 2025 | Ponvory |
| Biogen, INC. | $47.96 | 2025 | Spinraza, Tysabri, Vumerity |
| Kedrion Biopharma, INC. | $38.76 | 2025 | Kedrab, Koate, Gammaked |
| Axsome Therapeutics, INC. | $34.42 | 2025 | Symbravo |
| Neurelis, INC. | $31.46 | 2024-2025 | Valtoco |
| Lundbeck LLC | $29.11 | 2025 | Vyepti |
| Abbvie INC. | $17.82 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.39 | 2025 | Rexulti |
| Lilly USA, LLC | $13.86 | 2025 | Amyvid, Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Warren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.